 NEW YORK and VIENNA, Austria., Oct. 14, 2021 GLOBE NEWSWIRE -- HOOKIPA Pharma Inc. NASDAQ: HOOK, HOOKIPA, a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the publication of a comprehensive review article on arenaviral immunotherapies in the peer-reviewed online journal, Frontiers in Oncology Link. The article reinforces the potential of HOOKIPAs versatile arenavirus platform as a promising strategy to elicit potent, tumor-specific T cell responses and help address critical unmet needs in the treatment of cancer. 